Jack Mardekian
About
Jack Mardekian is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Jack Mardekian has authored 223 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Cardiology and Cardiovascular Medicine, 46 papers in Internal Medicine and 40 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jack Mardekian's work include Atrial Fibrillation Management and Outcomes (85 papers), Venous Thromboembolism Diagnosis and Management (46 papers) and Cardiac Arrhythmias and Treatments (37 papers). Jack Mardekian is often cited by papers focused on Atrial Fibrillation Management and Outcomes (85 papers), Venous Thromboembolism Diagnosis and Management (46 papers) and Cardiac Arrhythmias and Treatments (37 papers). Jack Mardekian collaborates with scholars based in United States, United Kingdom and Denmark. Jack Mardekian's co-authors include Xianying Pan, Gregory Y.H. Lip, Allison Keshishian, Xuemei Luo, Shital Kamble, Anagha Nadkarni, Andreas Kuznik, Kiran Gupta, Cristina Masseria and Xiaoyan Li and has published in prestigious journals such as JAMA, Circulation and Journal of Clinical Oncology.
In The Last Decade
Jack Mardekian
222 papers receiving 4.1k citations
Peers
Jack Mardekian
Andrea Roalfe United Kingdom
Maura Marcucci Italy
Adam J. Rose United States
Joseph Menzin United States
Kasper Adelborg Denmark
Xavier Kurz Netherlands
Arlene M. Gallagher United Kingdom
Rory Collins United Kingdom
Yea‐Huei Kao Yang Taiwan
Alanna M. Chamberlain United States
Citations per year, relative to Jack Mardekian Jack Mardekian (= 1×)
peers
Andrea Roalfe
Countries citing papers authored by Jack Mardekian
Since
Specialization
Citations
This map shows the geographic impact of Jack Mardekian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jack Mardekian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jack Mardekian more than expected).
Fields of papers citing papers by Jack Mardekian
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jack Mardekian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jack Mardekian. The network helps show where Jack Mardekian may publish in the future.
Co-authorship network of co-authors of Jack Mardekian
This figure shows the co-authorship network connecting the top 25 collaborators of Jack Mardekian. A scholar is included among the top collaborators of Jack Mardekian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jack Mardekian. Jack Mardekian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Freedland, Stephen J., Krishnan Ramaswamy, Rickard Sandin, et al.. (2023). Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 21(4). 419–429.
2.
Elkin, Peter L., Sarah Mullin, Jack Mardekian, et al.. (2021). Using Artificial Intelligence With Natural Language Processing to Combine Electronic Health Record’s Structured and Free Text Data to Identify Nonvalvular Atrial Fibrillation to Decrease Strokes and Death: Evaluation and Case-Control Study. Journal of Medical Internet Research. 23(11). e28946–e28946.
3.
Kuchta, Kristine, Andres Quintero, Patrick Hlavacek, et al.. (2020). National Physician Survey for Nonvalvular Atrial Fibrillation (NVAF) Anticoagulation Comparing Knowledge, Attitudes and Practice of Cardiologist to PCPs. Clinical and Applied Thrombosis/Hemostasis. 26. 2874351078–2874351078.
4.
Bartlett, Cynthia Huang, Jack Mardekian, Matthew J. Cotter, et al.. (2020). Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer. PLoS ONE. 15(4). e0227256–e0227256.
5.
Wilson, Lauren E., Xuemei Luo, Xiaoyan Li, et al.. (2019). Clinical outcomes and treatment patterns among Medicare patients with nonvalvular atrial fibrillation (NVAF) and chronic kidney disease. PLoS ONE. 14(11). e0225052–e0225052.
6.
Deitelzweig, Steven, Allison Keshishian, Amiee Kang, et al.. (2019). EFFECTIVENESS AND SAFETY OF APIXABAN, DABIGATRAN AND RIVAROXABAN VERSUS WARFARIN IN OBESE PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION: ARISTOPHANES SUBGROUP ANALYSIS. Journal of the American College of Cardiology. 73(9). 435–435.
7.
Deitelzweig, Steve, Allison Keshishian, Xiaoyan Li, et al.. (2017). Abstract 16462: Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Among Non-Valvular Atrial Fibrillation Patients: A Propensity Score Matched Analysis of Four Large Databases. Circulation.
8.
Deitelzweig, Steven, Xuemei Luo, Kiran Gupta, et al.. (2017). REAL WORLD EVALUATION OF MAJOR BLEEDING RISK AND COSTS FOR ALL CAUSES AND BLEEDING-RELATED HEALTH SERVICES AMONG ELDERLY PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION TREATED WITH APIXABAN OR WARFARIN. Journal of the American College of Cardiology. 69(11). 312–312.
9.
Lip, Gregory Y.H., Xianying Pan, Shital Kamble, et al.. (2016). Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States. International Journal of Clinical Practice. 70(9). 752–763.
10.
Horblyuk, Ruslan, Jack Mardekian, Sang Hee Park, et al.. (2016). Abstract 13828: Real World Bleeding Risks in Non-valvular Atrial Fibrillation Patients With Heart Failure: Contemporary EHR Results Among Prescribed Apixaban, Dabigatran, Rivaroxaban and Warfarin. Circulation. 134(suppl_1).
11.
Deitelzweig, Steve, Xuemei Luo, Kiran Gupta, et al.. (2016). Abstract 17298: Real-world Evaluation of Healthcare Resource Use and Costs of Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Apixaban vs. Warfarin in the US. Circulation. 134.
12.
Pasquale, Margaret K., et al.. (2016). ULCERATIVE COLITIS TREATMENT PATTERNS AND COST OF CARE. Value in Health. 19(3). A314–A314.
13.
Trocio, Jeffrey, Amanda Bruno, Prianka Singh, et al.. (2015). Treatment and Discharge Patterns Among Patients Hospitalized With Nonvalvular Atrial Fibrillation (NVAF) Who Transition From the Inpatient to Outpatient Setting. CHEST Journal. 148(4). 66A–66A.
14.
Hylan, Timothy R., Michael Von Korff, Kathleen Saunders, et al.. (2015). Automated Prediction of Risk for Problem Opioid Use in a Primary Care Setting. Journal of Pain. 16(4). 380–387.
15.
Allen, Harris, Jack Mardekian, Raymond Cheung, et al.. (2014). Tracking Low Back Problems in a Major Self-Insured Workforce. Journal of Occupational and Environmental Medicine. 56(6). 604–620.
16.
Michna, Edward, Wendy Y. Cheng, Caroline Korves, et al.. (2013). Systematic Literature Review and Meta-Analysis of the Efficacy and Safety of Prescription Opioids, Including Abuse-Deterrent Formulations, in Non-Cancer Pain Management. Pain Medicine. 15(1). 79–92.
17.
Pleil, Andreas M., Jack Mardekian, & Jane Loftus. (2011). Diabetic Macular Edema (DME) and Treatment of the Better-Seeing Eye - An Experimental Bias for Vision-Related Quality of Life (VRQoL) Outcomes?. Investigative Ophthalmology & Visual Science. 52(14). 577–577.
18.
Mychaskiw, Marko A., et al.. (2010). Relationship Between Pulmonary Vascular Resistance and Physical Functioning in Two Randomized Controlled Trials of Adult Patients With Pulmonary Arterial Hypertension, Including Those With Associated Connective Tissue Disease. CHEST Journal. 138(4). 363A–363A.
19.
Cappelleri, Joseph C., et al.. (2010). Physical Functioning, Six-Minute Walk Distance, and Pulmonary Vascular Resistance in Adult Patients With Pulmonary Arterial Hypertension Treated With Sildenafil: Examining the Distributions of Outcomes. CHEST Journal. 138(4). 362A–362A.
20.
Jensen, Mark P., Jack Mardekian, Mani Lakshminarayanan, & Mark E. Boye. (2007). Validity of 24-h recall ratings of pain severity: Biasing effects of “Peak” and “End” pain. Pain. 137(2). 422–427.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Andrea Roalfe Breakdown of academic impact, for papers by Maura Marcucci Breakdown of academic impact, for papers by Adam J. Rose Breakdown of academic impact, for papers by Joseph Menzin Breakdown of academic impact, for papers by Kasper Adelborg Breakdown of academic impact, for papers by Xavier Kurz Breakdown of academic impact, for papers by Arlene M. Gallagher Breakdown of academic impact, for papers by Rory Collins Breakdown of academic impact, for papers by Yea‐Huei Kao Yang Breakdown of academic impact, for papers by Alanna M. Chamberlain